Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (231-240 of 286) with videos related to

Pageof 29
Sort By:
Lancet (London, England)|March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Gastroenterology|February 15, 2017
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S Hyams, Marla C Dubinsky, Robert N Baldassano, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|May 14, 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's diseaseMarla C Dubinsky, Subra Kugathasan, Soonil Kwon, et al.
Nature Reviews. Gastroenterology & Hepatology|April 22, 2025
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health responseVirginia Solitano, Charles N Bernstein, Iris Dotan, et al.
Journal of Crohn'S & Colitis|October 6, 2021
Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus StatementJohan F K F Ilvemark, Tawnya Hansen, Thomas M Goodsall, et al.
Gut|January 25, 2011
Variants in ZNF365 isoform D are associated with Crohn's diseaseTalin Haritunians, Michelle R Jones, Dermot P B McGovern, et al.
JCI Insight|September 21, 2018
Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's diseaseDaniel Kelly, Michael Kotliar, Vivienne Woo, et al.
Pageof 29

Showing results (231-240 of 286) with videos related to

Sort By:
Pageof 29
Lancet (London, England)|March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Gastroenterology|February 15, 2017
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S Hyams, Marla C Dubinsky, Robert N Baldassano, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|May 14, 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's diseaseMarla C Dubinsky, Subra Kugathasan, Soonil Kwon, et al.
Nature Reviews. Gastroenterology & Hepatology|April 22, 2025
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health responseVirginia Solitano, Charles N Bernstein, Iris Dotan, et al.
Journal of Crohn'S & Colitis|October 6, 2021
Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus StatementJohan F K F Ilvemark, Tawnya Hansen, Thomas M Goodsall, et al.
Gut|January 25, 2011
Variants in ZNF365 isoform D are associated with Crohn's diseaseTalin Haritunians, Michelle R Jones, Dermot P B McGovern, et al.
JCI Insight|September 21, 2018
Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's diseaseDaniel Kelly, Michael Kotliar, Vivienne Woo, et al.
Pageof 29